---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-005063"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-07-21T23:59:59+00:00"
generated_at: "2026-06-24T09:52:30.545149+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech commences pilot phase of pig study to address FDA clinical hold for pancreatic cancer trial

## Summary
- Pilot study in two Yorkshire pigs evaluates microcatheter delivery of CypCaps into pancreatic arterial system.
- Data will finalize full-scale 90-pig study protocol; results to be presented to FDA in Type A meeting.
- Study aims to lift clinical hold on planned Phase 2b trial for locally advanced inoperable pancreatic cancer (LAPC).
- CypCaps contain radiopaque microspheres to track movement via imaging and histology over one-week observation.
- Study conducted by CBSET, Inc. in Lexington, MA.

## SEC filing metadata
- accession: 0001683168-22-005063
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-07-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005063/0001683168-22-005063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005063/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-005063
- JSON: https://secwatch.observer/filing/0001683168-22-005063.json
- Plain text: https://secwatch.observer/filing/0001683168-22-005063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.